Important caution: Given the dual role of glutathione in cancer biology, glutathione or NAC supplementation should NOT be taken during active cancer treatment without oncologist approval, as it could theoretically protect tumor cells from therapy [2][5]

A small portion of these have been confirmed to alter such responses when consumed at reasonable oral doses in human or animals and are listed below: 7 Cruciferous glucosinolates (broccoli, Brussels sprouts, etc.) 8,9,10 Sulforaphane (concentrated) 11,12 Curcuminoids (turmeric) 13,14 Quercetin 15,16 Resveratrol 17,18 Phenethyl isothiocyanate (PEITC, from watercress) 19,20 Diallyl sulfide (garlic) 21,22 Lipoic acid 23,24 N-acetyl cysteine (NAC) 25,26 Additional Nrf2-Modulating Ingredients The list of natural compounds shown to modulate Nrf2 pathways or ARE-containing genes is too numerous to list in this text, though common ingredients for which the reader might be familiar include all those listed above and also baicalein ( Scutellaria baicalensis ), catechins (tea, cocoa), genistein (soy), carnosol and carnosic acid ( Rosmarinus officinalis ), andrographolide ( Andrographis paniculata ), ginsenoside Rb1 ( Panax ginseng ), schisandrin B ( Schisandra chinensis ), quercetin and related flavonoids, indole-3-carbinol (I3C) and diindolylmethane (DIM), hydroxytyrosol ( Olea europaea - olive), Pterostilbene, Xanthohumol ( Humulus lupulus ), berberine, [6]-gingerol ( Zingiber officinale ), vitamin D, and even exercise (though the Nrf2-activation response decreases with aging)

The Short List of Popular GLP-1 Medications Most comparisons include these popular GLP-1 medications: Semaglutide: GLP-1 agonist that is available as a weekly injection or an oral form Tirzepatide: Dual GIP/GLP-1 agonist available as a weekly injection with a broader incretin target Each GLP-1 medication has specific approvals, contraindications, and titration protocols
GLP-1 (glucagon-like peptide-1) is a hormone that regulates appetite and glucose metabolism
GLP-1 RA medications are having their moment
2004 Oct;134(10 Suppl):2743S-7S